IMRT

 First analysis of data from phase 3 randomised trials comparing SABR with surgery  First report to suggest that SABR is better tolerated and might lead to better OS compared to surgery for operable clinical stage I NSCLC  Results are compatible with the notion that the two therapies are equally effective with lower survival after surgery possibly resulting from comorbidities worsened by the surgical reduction of lung function

BUT…

Small patients sample size and short follow-up

 These findings nevertheless strongly suggest at least equipoise between the two modalities and support the initiation of larger randomised studies to validate these findings